Holen Sie sich die Stockscreener-App
0.4145
2.47%
-0.0105
Handel nachbörslich:
2.66
2.2455
+541.74%
Gt Biopharma Inc Aktie (GTBP) Neueste Nachrichten
GT Biopharma (GTBP) Develops 'Hammer Chart Pattern': Is It an Opportunity to Buy at the Bottom? - Bitget
GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
GT Biopharma to Participate in the 38th Annual Roth Conference - Bitget
GT Biopharma, Inc. Files Restated Q3 2025 10-Q/A Due to Greenshoe Rights Liability Accounting Error - Minichart
GT Biopharma, Inc. 2025 Q2 Amended Quarterly Report (10-Q/A): Restatement Due to Greenshoe Rights Liability, Financial Statements & SEC Compliance - Minichart
Will GT Biopharma Inc. (OXIA) stock beat value stocksWeekly Profit Summary & Technical Pattern Based Buy Signals - Naître et grandir
Stock Market Recap: Can GT Biopharma Inc outperform under higher oil pricesJuly 2025 Momentum & Consistent Return Investment Signals - baoquankhu1.vn
GTBP Earnings History & Surprises | EPS & Revenue Results | GT BIOPHARMA INC (NASDAQ:GTBP) - ChartMill
GTBP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GTBPForm 8-KCurrent report - ADVFN Ltd
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
GT Biopharma to restate 2025 financials after error in Greenshoe Rights accounting - Investing.com UK
GT Biopharma to restate 2025 financials after error in Greenshoe Rights accounting By Investing.com - Investing.com South Africa
GTBP: Net loss increased to $28.4M in 2025, with cash runway projected through Q4 2026 - TradingView
GT Biopharma 2025 10‑K: $0 Revenue, $(6.68) EPS, $28.35M net loss - TradingView
GT Biopharma (NASDAQ: GTBP) details cash strain, losses and $20M equity line - Stock Titan
GTBP: Net loss rose to $28.4M in 2025, with ongoing liquidity risks and urgent need for new capital - TradingView
Restatement of 2025 quarters at GT Biopharma (NASDAQ: GTBP) - Stock Titan
GT Biopharma Reports Full Year 2025 Financial Results - marketscreener.com
Cancer trial firm GT Biopharma says $9M cash funds work into late 2026 - Stock Titan
Should I Buy GTBP? GTBP 2026 AnalysisIntellectia AI™ - Intellectia AI
GT Biopharma (GTBP) Gets FDA Green Light to Test New Cancer-Fighting Tech in Humans - Barchart.com
Can GT Biopharma Inc. outperform under higher oil pricesJuly 2025 Snapshot & Verified Swing Trading Watchlist - mfd.ru
Why GT Biopharma Inc. (OXIA) stock could be top winnerPortfolio Growth Summary & Technical Analysis for Trade Confirmation - mfd.ru
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference - The Manila Times
Risk Recap: Is GT Biopharma Inc stock a top performer YTDPortfolio Return Summary & AI Forecasted Stock Moves - baoquankhu1.vn
Rate Hike: Is GT Biopharma Inc. stock a safe investment in uncertain markets2025 Trading Recap & Real-Time Stock Entry Alerts - mfd.ru
GT Biopharma (GTBP) Expected to Announce Quarterly Earnings on Friday - Defense World
How GT Biopharma Inc. stock reacts to job market dataWeekly Trade Report & Verified Short-Term Plans - mfd.ru
How do insiders feel about GT Biopharma Inc.2025 Key Highlights & Expert Verified Movement Alerts - mfd.ru
Will GT Biopharma Inc. stock remain a Wall Street favoriteProfit Target & Reliable Price Action Trade Plans - mfd.ru
How GT Biopharma Inc. stock trades before earningsStock Surge & Intraday High Probability Alerts - mfd.ru
Ellis Martin Report: GT Biopharma, Inc. (NAS - marketscreener.com
Ellis Martin Report: GT Biopharma, Inc. (NASDAQ:GTBP) Advances Platform Immuno-Oncology Strategy with FDA-Cleared Solid Tumor IND; An Interview with CEO Michael Breen - ABN Newswire
GT Biopharma Submits IND for Solid Tumor Immunotherapy Targeting Portion of $362 Billion Market as Cash Position Nearly Triples - Barchart.com
Is GT Biopharma Inc. stock a good choice for value investorsJuly 2025 Setups & Free Daily Entry Point Trade Alerts - mfd.ru
GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug for GTB-5550 TriKE, B7-H3-Targeted Natural Killer Cell Engager for Solid Tumors Expressing B7-H3 - marketscreener.com
GT Biopharma gets FDA IND clearance for GTB-5550 TRiKE, B7-H3-targeted NK engager for B7-H3+ solid tumors - marketscreener.com
GT Biopharma surges as FDA clears human trial for new cancer drug - TradingView
GT Biopharma Announces FDA Clearance for GTB-5550 Phase 1 Clinical Trial Targeting Solid Tumors Expressing B7-H3 - Quiver Quantitative
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 - marketscreener.com
GT Biopharma Announces FDA Clearance of Investigational New - GlobeNewswire
What analysts say about GT Biopharma Inc stock2025 Top Decliners & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
GT Biopharma, Inc. (NASDAQ:GTBP) Sees Large Increase in Short Interest - Defense World
Published on: 2026-01-18 22:59:36 - baoquankhu1.vn
Hedge Fund Bets: Will GT Biopharma Inc benefit from government policy2025 Fundamental Recap & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle - The Manila Times
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape - The AI Journal
GT Biopharma submits IND application for solid tumor cancer treatment By Investing.com - Investing.com Nigeria
GT Biopharma submits IND application for solid tumor cancer treatment - Investing.com
GT Biopharma Submits IND Application for GTB-5550 to Target $362 Billion Solid Tumor Market | GTBP Stock News - Quiver Quantitative
New immune-based drug to test B7-H3 solid tumors across 7 cancers in trial - Stock Titan
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):